Background
==========

Peritoneal dialysis-associated peritonitis (PD-peritonitis) due to *Mycobacterium spp* is uncommon, particularly in patients receiving treatment in developed countries. Non-tuberculous *Mycobacterium* (NTB) PD-peritonitis can present in a similar fashion to more common causes of bacterial PD-peritonitis. However, treatment is often complicated by apparent culture negative dialysate effluent, prolonged treatment courses requiring multiple antibiotics and Tenckhoff catheter removal requiring a change to haemodialysis. We describe the first case of *M. fortuitum* PD-peritonitis in an Australian patient, requiring Tenckhoff catheter removal and permanent conversion to haemodialysis. The literature is reviewed regarding the presentation and treatment of this condition.

Case presentation
=================

A 38 year-old woman with end-stage renal disease due to Factor-H deficient haemolytic uraemic syndrome had been treated with peritoneal dialysis for 6 months without complication. The patient practiced continuous ambulatory peritoneal dialysis with four exchanges per day of two litres of 2.5% dextrose, each of 4 hour duration. The patient had no prior comorbidities nor history of significant infections. She embarked on a cruise ship holiday in the Pacific. Three days after arriving in North America, she developed nausea which progressed over one week to include mild abdominal pain and diarrhoea. Although her dialysate effluent was cloudy, the mildness of her symptoms prompted the patient to continue the final two weeks of her holiday without any antibacterial treatment. She had no exit site symptoms at any point and reported adherence to her aseptic technique training. Upon return to Australia she promptly presented to hospital.

On presentation to hospital she was febrile (38°C) and tachycardic (108 beats/minute) with a blood pressure of 112/85 mmHg. On examination she had mild abdominal distension and right iliac fossa tenderness. Bowel sounds were present and the Tenckhoff catheter exit site was unremarkable. The peritoneal fluid was turbid with \>100 x10^6^/mL leukocytes, predominantly neutrophils.

The peritoneal dialysate cultures were initially reported as culture negative and the patient was treated empirically with intraperitoneal vancomycin and gentamicin. After an early clinical improvement she developed a recurrence of fever and abdominal pain four days after admission. An abdominal computerised tomography scan demonstrated multiple loculations with thin high attenuation rims (Figure [1](#F1){ref-type="fig"}.). Concurrently, the initial dialysate effluent samples grew gram-positive bacilli after four days consistent with a rapidly-growing non-tuberculous mycobacterium. Gene sequencing by polymerase chain reaction of the isolate identified it to be *M. fortuitum*. Subsequent antibiotic susceptibility testing demonstrated sensitivity to amikacin and ciprofloxacin, intermediate resistance to cefoxitin, and resistance to clarithromycin, doxycycline, imipenem and trimethoprim/sulfamethoxazole.

![Computerised tomography of the abdomen, demonstrating multiple loculations with thin high attenuation rims.](1471-2369-13-35-1){#F1}

The patient underwent surgical removal of the Tenckhoff catheter, disruption of loculations and lavage of the peritoneal space. Her subsequent antibiotic regimen of oral moxifloxacin, clarithromycin and doxycycline was complicated by the development of intolerable nausea. She was then established on oral moxifloxacin and linezolid for six months with a sustained clinical response. Treatment duration was empirically determined. After completion of her course of antibiotics re-insertion of the Tenckhoff catheter was attempted but abandoned after multiple intraperitoneal adhesions were found.

Literature review
=================

We conducted a systematic review of the literature of *M. fortuitum* PD-peritonitis. 17 reports were identified occurring in 12 males and 5 females aged between 15 and 83 years (Table [1](#T1){ref-type="table"}.). The geographic spread included reports from North America (8 patients), Asia (4 patients), Europe (3 patients) and the Middle East (2 patients) with none from Australia.

###### 

**Published reports of*M fortuitum*PD-peritonitis**

  **Location of the report**                                                            **Patient demographics**   **Time from admission to positive culture**                          **Sensitivity**                                                                                           **Directed Treatment**                                                          **Tenckhoff removed**   **Comment**
  ------------------------------------------------------------------------------------- -------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ----------------------- -----------------------------------------------------------
  Houston, USA \[[@B1]\]                                                                15 y/o male                4 days                                                               S -- Amikacin, trimethoprim/sulfamethoxazole, cefoxitin                                                   IV Amikacin and IV cefoxitin. (^c^)                                             Yes                     Abscess drainage required
  R- doxycycline                                                                                                                                                                                                                                                                                                                                                                                          
  Portland, USA \[[@B2]\]                                                               57 y/o male                7 days                                                               Not reported                                                                                              PO Erythromycin, IV cephapirin, IV tobramycin.(6 days)                          Yes                     Catheter leak. No abdominal pain. Patient died at 6 days.
  Copenhagen, Denmark \[[@B3]\]                                                         35 y/o male                11 days                                                              S -- Amikacin, tobramycin, erythromycin, trimethoprim-sulfamethoxazole                                    IV Amikacin, IV methicillin (^c^)                                               Yes                     In renal transplant perioperative period.
  Cleveland, USA \[[@B4]\]                                                              32 y/o male                6 days                                                               S -- Amikacin, tetracycline                                                                               Amikacin, tetracycline (1 month); ciprofloxacin (^c^, ^d^)                      Yes                     Reduced aural acuity after amikacin.
  R -- gentamicin, tobramycin, erythromycin, trimethoprim/sulfamethoxazole                                                                                                                                                                                                                                                                                                                                
  Hong Kong, China \[[@B5]\]                                                            65 y/o male                \-                                                                   Not reported                                                                                              PO Levofloxacin, PO clarithromycin (12 months)                                  No                       
  Seoul, Korea \[[@B6]\]                                                                54 y/o female              7 days                                                               R -- isoniazid, rifampicin, ethambutol, streptomycin                                                      IV Ceftizotime, IV amikacin (^c^)                                               Yes                      
  Louisiana, USA^b^\[[@B7]\]                                                            71 y/o male                7 days                                                               Not reported                                                                                              IP Amikacin and cefoxitin (3 weeks); PO doxycycline and rifampicin (3 months)   Yes                      
  83 y/o female                                                                         4 days                     Not reported                                                         Ciprofloxacin and clofazimine (^c^, ^d^)                                                                  ?                                                                                                       
  Madrid, Spain \[[@B8]\]                                                               42 y/o male                11 days                                                              Not reported                                                                                              IV Amikacin and PO doxycycline (20 days)                                        Yes                      
  40 y/o male                                                                           8 days                     Not reported                                                         IV Amikacin and PO doxycycline (1 month)                                                                  Yes                                                                                                     
  Washington, USA \[[@B9]\]                                                             33 y/o male                7 days                                                               S -- amikacin, kanamycin, clarithromycin, cefmetazole, imipenem, ciprofloxacin, ofloxacin, azithromycin   PO Clarithromycin and PO trimethoprim/sulfamethoxazole (6 months)               Yes                      
  71 y/o female                                                                         4 days                     R -- tobramycin, erythromycin, doxycycline, minocycline, cefoxitin   IV Amikacin, PO clarithromycin, PO trimethoprim/sulfamethoxazole (3 months)                               Yes                                                                                                     
  S -- clarithromycin, cefmetazole, imipenem, sulfisoxazole, ciprofloxacin, ofloxacin                                                                                                                                                                                                                                                                                                                     
  I -- amikacin, cefoxitin                                                                                                                                                                                                                                                                                                                                                                                
  Saudi Arabia \[[@B10]\]                                                               45 y/o female              7 days                                                                                                                                                                         PO Isoniazid, rifampicin, ethambutol. (6 months)                                Yes                      
  Nashville, USA \[[@B11]\]                                                             16 y/o male                12 days                                                                                                                                                                        PO Ciprofloxacin, PO trimethoprim/sulfamethoxazole (^c^)                        Yes                     Perihepatic collection
  Kfar-Saba, Israel \[[@B12]\]                                                          65 y/o male                4 days                                                                                                                                                                         Minocycline (1 month^d^)                                                        Yes                     Also bacteraemia
  Tokyo, Japan \[[@B13]\]                                                               50 y/o male                3 weeks                                                              Not reported                                                                                              Amikacin, sulbactam (^c^,^d^)                                                   Yes                      
  Singapore, Singapore ^b^\[[@B14]\]                                                    78 y/o female              8 days                                                               S -- tobramycin, linezolid, clarithromycin, amikacin                                                      IP amikacin, PO ciprofloxacin (3 months)                                        No                      Patient died at 2 months from malignancy

^a^This publication also reported on a suspected case of PD-peritonitis and two confirmed cases of Tenckhoff catheter exit site infections due to *M. fortuitum*.

^b^This publication also listed a second (male) patient with *M. fortuitum* PD-peritonitis in a table, but described the patient to be a female with *M. abscessus* PD-peritonitis in the text. Due to inconsistency in the report, this case was excluded.

^c^Duration of therapy not known.

^d^Route of administration not known.

*IP* intraperitoneal, *PO* per oral, *IV* intravenous.

The duration of symptoms prior to hospital presentation was incompletely reported and a delay in microbiological diagnosis was commonplace (median 7 days, interquartile range 4-8 days). Intra-abdominal loculations and collections occurred in 2 previous reports*.* The Tenckhoff catheter was removed in all but two reported cases and mostly at the time of diagnosis. The duration of antibiotic therapy varied widely (between 1 and 12 months), so the optimum treatment appears to be poorly defined. In our patient the 6 month duration was chosen based on typically reported dosing periods. Antibiotic sensitivity by disc diffusion was reported in 10 of the 17 reports. *M. fortuitum* was almost universally sensitive to amikacin, ciprofloxacin, imipenem and clarithromycin. Resistance to cephalosporins, tetracyclines and other macrolides was variable. Similarly, there was marked variability in the antibiotic regimens utilised and the rationale for these choices were incompletely described. The more common antibiotics utilised included amikacin in 7 reports, ciprofloxacin in 4 reports and doxycycline in 3 reports with combination therapy common. Only one death was reported in a patient with *M. fortuitum* PD-peritonitis (Table [1](#T1){ref-type="table"}).

Conclusion
==========

We describe the first case of *M. fortuitum* PD-peritonitis and the third case of any NTM PD-peritonitis in an Australian patient \[[@B15],[@B16]\]. The place and mode of infection remain unclear. Our patient had recently returned from a one month overseas holiday traversing the Pacific, the Caribbean and North America. Given the slow growth rate of *M. fortuitum* her peritoneum may have been inoculated either before leaving Australia, whilst travelling through the Caribbean or North America. The slow growth rate of *M. fortuitum* presumably accounts for the mild and indolent development of symptoms and may be a clinical characteristic of NTM PD-peritonitis. The subacute course may predispose to the chronic sequelae of infection. Our case brings the number of cases with reported intra-abdominal loculations to three in eighteen. This proportion could well be an underestimate with only a minority of reported patients having imaging or persisting with peritoneal dialysis.

The incidence of PD-peritonitis due to *Mycobacterium spp.* in Australia has not been described. On the basis of registry data, it is anticipated to be low given the relatively high cure rates of all cases of PD-peritonitis in Australia after a median duration of treatment of 13 days with primarily vancomycin or cephalosporins with/without gentamicin \[[@B17]\]. There is considerable variability in the proportion of cases of PD-peritonitis that are culture-negative in Australian and New Zealand renal units which may reflect differences in disease prevalence and/or diagnostic and management practices \[[@B17]\].

Guidelines of the International Society of Peritoneal Dialysis (ISPD) recommend that a negative dialysate culture at 3 days in the presence of ongoing clinical evidence of peritonitis calls for specialized cultures for atypical causes of peritonitis \[[@B18]\]. If there is a clinical suspicion of infection with *Mycobacterium spp.*, repeated smears and centrifuge of effluent sediment with a combination of solid- and fluid-medium culture are suggested.

The safety and timing for attempted re-insertion of Tenckhoff catheters after treatment, and technique survival, is incompletely reported. The ISPD guidelines recommend consideration of catheter removal following a diagnosis of Mycobacterial peritonitis although data supporting this recommendation are limited.

Non-tuberculous Mycobacteria are a rare but serious cause of PD-peritonitis with high rates of Tenckhoff removal and conversion to haemodialysis. This is the first report of *M. fortuitum* PD-peritonitis reported in Australia and the diagnosis was prompted by inadequate response to empiric antibiotics and confirmed by special investigations that are uncommonly utilised in most cases of PD-peritonitis.
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